https://doi.org/10.33472/AFJBS.6.10.2024.541-555

African Journal of Biological Sciences

Development And Evaluation Of Phytosomes For The Treatment Of Malaria: A Review

Maryam Musa Kallah[1*], Manish Yadav[2], Mohit Mangla[3]

[1*,2,3]School of Medical and Allied Science, G D Goenka University, Gurgaon

Corresponding Author:- Maryam Musa Kallah
School of Medical and Allied Science, G D Goenka University, Gurgaon

Article History
Volume 6, Issue 10, 2024
Received: 17 Apr 2024
Accepted : 03 May 2024
Doi :10.33472/AFJBS.6.10.2024.541-555

Abstract

Malaria, caused by parasites transmitted through Anopheles mosquitoes, remains a significant global health concern, with substantial morbidity and mortality rates. This review explores the development and evaluation of phytosomes as a promising approach for malaria treatment. Phytosomes, encapsulating hydrophilic bioactive phytoconstituents within phospholipid complexes, offer enhanced drug delivery and bioavailability compared to traditional herbal extracts. Various methods, including solvent evaporation, mechanical dispersion, and anti-solvent precipitation, are employed for phytosomes preparation. Evaluation techniques such as scanning electron microscopy, dynamic light scattering, and spectrophotometry are utilized to assess their characteristics and efficacy. Furthermore, challenges, future directions, and the role of phytosomes in malaria treatment are discussed, highlighting their potential as a novel therapeutic strategy.

KEY WORDS- malaria, quinine, phytosomes.

INTRODUCTION

Overview of malaria and its global impact

Malaria is a disease caused by parasites transmitted through the bite of female Anopheles mosquitoes. There are various species of Plasmodium parasites, but only five affect humans: Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi. Among these, P. falciparum is responsible for most malaria-related deaths worldwide. While P. vivax was traditionally thought to cause mild malaria, there is evidence suggesting its potential to cause severe illness. P. knowlesi, transmitted from primates, can also lead to severe complications in humans. P. malariae and P. ovale typically cause uncomplicated malaria, although complications are rare [1]. Malaria poses a significant public health challenge, causing substantial illness and death. Despite being preventable and treatable, malaria remains a serious threat to people's well-being and economic stability worldwide. Nearly half of the global population, residing in approximately 100 countries and territories, is vulnerable to malaria. According to the World Health Organization (WHO) in 2018, there were an estimated 228 million malaria cases globally, with the majority occurring in the WHO Africa Region (93%). WHO also reported

approximately 405,000 malaria-related deaths in 2018, with children under 5 years old accounting for 67% of the total malaria fatalities worldwide [2].

In the context of the relationship between climate and health, numerous research works have explored how climatic factors affect the spread of malaria. Changes in climate, particularly rising temperatures, can alter malaria transmission patterns. Higher temperatures can shorten the time it takes for the malaria parasite to reproduce inside mosquitoes. Additionally, variations in the intensity and frequency of precipitation can impact the growth of mosquito populations [3]. Sufficient humidity is crucial for the survival of mosquitoes because they are highly vulnerable to drying out. Elevated humidity levels often occur before significant rainfall, especially during warm temperatures, as moisture from the ground evaporates but is trapped by incoming clouds. Close to the ground, when relative humidity is high, mosquitoes experience better survival rates, increased flight activity, and more active searching for hosts. These conditions are conducive to the transmission of malaria, particularly within an optimal relative humidity range of approximately 60–80% [4].

PATHOPHYSIOLOGY/MECHANISM

When an infected mosquito injects Plasmodium sporozoites into a host, they travel to the liver and commence the hepatic phase of the parasite's life cycle. Within hepatocytes, they multiply and transform into schizonts containing numerous hepatic merozoites. These merozoites are then released into the bloodstream, where they begin the erythrocytic stage by invading and reproducing within red blood cells (RBCs). Some of these asexual blood parasites mature into gametocytes, facilitating transmission to the mosquito vector. In the cases of P.vivax and P.ovale, the life cycle within the mammalian host differs slightly. Certain sporozoites, upon reaching the liver, do not immediately mature into schizonts but instead remain in a quiescent form known as hypnozoites. These hypnozoites may lay dormant for weeks, months, or even years before resuming hepatic development, triggering relapses of the infection due to factors that are not yet fully understood (fig. 1) [5].



Fig 1.

CURRENT TREATMENT APPROACHES OF MALARIA

1.Artemisinin-based Combination Therapies (ACTs)

A. Artesunate + pyronaridine: A thorough examination of the combined therapy of artesunate and pyronaridine involved analyzing six studies with a total of 3718 participants. The results indicate that in adults and older children with P. falciparum malaria, this combination showed effective outcomes when compared to other commonly used treatments such as artemether + lumefantrine and artesunate + mefloquine. However, there is not enough evidence to confidently state its effectiveness in young children. Moreover, regulatory agencies noted slightly elevated levels of liver enzymes in patients treated with artesunate + pyronaridine compared to those in the control groups, prompting further investigation into the potential risk of liver toxicity associated with this treatment regimen [6].

B. Arterolane + piperaquine: is a blend of a man-made ozonide and piperaquine phosphate, approved for adult use in India exclusively. At present, there isn't enough information available to provide overarching recommendations [7,8].

C. Artemisinin + piperaquine: The combination of artemisinin + piperaquine base merges two widely accepted and well-tolerated substances. It diverges from prior therapies as it features piperaquine in its base form, a relatively low dosage of artemisinin, and the current prescription is for a 2-day treatment course only. However, there's a lack of comprehensive clinical trial data to offer a universal recommendation. There's also apprehension that the dosage of artemisinin may not provide adequate defense against resistance to the piperaquine element [9,10].

D. Artemisinin + naphthoquine: The combination of artemisinin + naphthoquine comprises two older compounds, which is presently being advocated as a single-dose treatment, going against the WHO's recommendation of a 3-day regimen for artemisinin derivatives. However, there is currently a lack of adequately conducted randomized controlled trials to provide universal recommendations [11].

2.Chloroquine: an antimalarial medication, was once extensively utilized to treat uncomplicated malaria resulting from chloroquine-sensitive strains of Plasmodium parasites. However, its application has been restricted to specific regions where the parasites are still responsive, primarily due to widespread resistance issues [12].

3.Mefloquine: Mefloquine was introduced for European travelers in 1985 under the brand name Lariam and has since been widely recommended for preventing malaria. Despite its effectiveness, it comes at a relatively high cost. Initial endorsement of the tolerability of weekly mefloquine prophylaxis was based on two uncontrolled observational studies published in a prestigious journal within a short timeframe. However, recent observational data has raised concerns about increased neuropsychological side effects in travelers using mefloquine compared to those using other standard prophylaxis. Anecdotal evidence suggesting heightened toxicity in mefloquine chemoprophylaxis has intensified the safety debate, particularly in Britain, Canada, and the Netherlands, leading to parliamentary inquiries and significant media attention [13].

4.Doxycycline: Doxycycline stands out among tetracyclines as the sole recommendation for anti-malarial prophylaxis. It took until 1994, 34 years after its development, for the Food and Drug Administration to approve doxycycline for malaria prevention. In regions with multi drug resistance, doxycycline is utilized as a chemoprophylaxis against P. falciparum, typically at a daily dose of 100mg starting upon arrival in endemic areas and continuing for up to 4 weeks after departure. This regimen, initially endorsed by the WHO in 1985, is based on earlier referenced studies [14,15].

5.Atovaquone - Proguanil: Both atovaquone and proguanil act against the pre-erythrocytic (hepatic) stages of P. falciparum, providing causal prophylaxis, and are effective against the erythrocytic parasite stage (suppressive prophylaxis) as well. Atovaquone demonstrated greater efficacy against different clones and isolates of P. falciparum during the erythrocytic stage in vitro compared to other antimalarial medications. The mean 50% inhibitory plasma concentrations (IC50) of atovaquone (ranging from 0.7 to 4.3 nmol/L) were lower than those of chloroquine, quinine, mefloquine, and artemether against various P. falciparum isolates. Atovaquone exhibited similar effectiveness against both chloroquine-sensitive and -resistant strains of P. falciparum [16].

6.Quinine: The traditional use of quinine for treating severe malaria has been questioned with the emergence of artemisinin derivatives. Initial clinical trials compared intramuscular artemether, a lipophilic form of dihydroartemisinic, with quinine. Artemether was found to be safer and more user-friendly than quinine, yet it did not enhance overall survival based on a meta-analysis of individual patient data from 1919 randomized patients. However, in a subgroup analysis, artemether demonstrated a significant reduction in mortality among southeast Asian adults but not African children. Following this, a large multi center trial, the Southeast Asian Quinine Artesunate Malaria Trial (SEAQUAMAT), compared intravenous artesunate with quinine in Asian patients, predominantly adults, with severe malaria. The trial was halted after enrolling 1461 patients due to a considerable survival advantage favoring artesunate. A meta-analysis combining data from SEAQUAMAT, and earlier smaller trials revealed that artesunate reduced severe malaria mortality in Asian patients from 23.1% to 14.2%, marking a relative decrease of 38.6%. Additionally, the treatment proved to be highly cost-effective. Consequently, in 2006, the WHO revised its guidelines to endorse artesunate as the preferred treatment for severe malaria in adults [17-20].

7. Primaquine: Since its introduction in 1950, Primaquine has been utilized to prevent relapse and sterilize infectious sexual plasmodia. However, its usage is surrounded by confusion due to the lack of comprehensive evaluation among the various regimens commonly employed. Primaquine tolerance by Plasmodium vivax is observed in Southeast Asia and Oceania, yet instances of therapeutic failure are seldom documented. Challenges such as poor adherence to primaquine

therapy and resistance to companion drugs like chloroquine further complicate matters. Additionally, abbreviated primaquine regimens lacking proven clinical efficacy are widely practiced. Contrary to its perceived toxicity and poor tolerance, available evidence suggests otherwise [21,22].



Fig.2 In randomized comparative controlled trials focusing on strictly defined severe falciparum malaria, mortality rates were examined across different treatment arms. These trials collectively enrolled 2,874 adults and 7,424 children. The size of the circle in the analysis roughly corresponded to the trial's magnitude, with error bars representing the 95% confidence intervals. Adults were primarily recruited from Southeast Asia, while children were predominantly enrolled in Africa [23].

NEW ANTIMALARIALS IN DEVELOPMENT

1. **Cipargamin**: Cipargamin (KAE609/NITD609) is an innovative Spiro-indolone compound used as an antimalarial drug. In a phase II clinical trial conducted in Thailand, administering cipargamin at a dosage of 30mg per day for three days resulted in a median parasite clearance time (PCT) of 12 hours for both Plasmodium falciparum and Plasmodium vivax infections. This performance is notably better than that of artemisinin-based treatments like artemether-lumefantrine (Coartem/Riamet; Novartis), which typically have median PCTs ranging from 24 to 44 hours [24,25].

2.Artefenomel: Artefenomel, also known as OZ439, is a synthetic peroxide compound that operates similarly to artemisinin in its mechanism of action. A study conducted in Thailand involving adult patients with uncomplicated malaria revealed that a single dose of artefenomel (ranging from 200 to 1200 mg) resulted in a parasite clearance half-life of 1.3-8.5 hours for P. falciparum infections, and the drug was well tolerated. In healthy volunteers, artefenomel exhibited a terminal half-life of approximately 30 hours, which was approximately 15 times longer than that of dihydroartemisinin. Furthermore, an oral dispersion formulation of artefenomel was found to enhance drug exposure, reduce variability between patients, and alleviate the impact of food on its efficacy [26].

3. Ganaplacide: Ganaplacide, an imidazolopiperazine compound, demonstrates potent activity in the nano molar range against various stages of the P. falciparum life cycle, including liver stage, asexual blood stage, and sexual blood stage. Both preclinical and clinical studies have confirmed its effectiveness against P. falciparum and Plasmodium vivax, and it has demonstrated transmission-blocking activity both in laboratory settings and in real-life situations. Additionally, ganaplacide exhibits causal prophylactic efficacy in the controlled human malaria infection (CHMI) model. Although its mechanism of action has yet to be fully understood, a related compound, GNF179,

belonging to the same imidazolopiperazine family, has been found to inhibit protein trafficking, impede the formation of new permeation pathways, and induce expansion of the endoplasmic reticulum [27].

4. Ferroquine: Ferroquine, along with other synthesized analogues created by substituting the dimethylamino side chain with different tertiary amino groups, demonstrated effectiveness against a chloroquine-resistant strain of P. falciparum during in vitro testing [28].

ROLE OF QUININE IN MALARIA TREATMENT

Quinine, originating from an alkaline extract of cinchona bark found in Andean forests, was the initial targeted medication for malaria infections. Its recognition supposedly began when it was administered to treat tropical fever in the Countess of Chinchon in Peru. Introduced to Europe as Jesuit's bark during the 17th century, its effectiveness claims often differed based on the nationality of the physicians as well as the quality, particularly bitterness, of the bark [29]. As far back as the Siege of Belgrade in 1717, cinchona bark was employed to combat malaria among soldiers. In 1777, James Lind, a member of the British Royal Navy, suggested that ships stationed on the Guinea coast (West Africa) should be equipped with ample amounts of powdered bark and wine. These supplies were to be distributed as needed to individuals traveling in boats up rivers and onshore [30].

Quinine was the conventional therapy for severe malaria over an extended period; however, it has been linked to treatment resistance and a range of adverse effects, including tinnitus, deafness, and hypoglycemia. Rapid intravenous administration can escalate to toxic levels, resulting in blindness and fatality [31].

CONCEPT OF PHYTOSOMES AND THEIR POTENTIAL IN DRUG DELIVERY

Phytosomes represent an innovative drug delivery system comprising hydrophilic bioactive phytoconstituents from herbs encapsulated and enveloped by phospholipids. This complex, resembling a miniature cell, offers improved pharmacokinetic and pharmacodynamic properties compared to traditional herbal extracts, leading to enhanced bioavailability. The binding of botanical extracts with phospholipids enhances their absorption in the intestinal tract, thereby boosting bioavailability. The formulation of phytosomes is considered safe, as all components are approved for pharmaceutical and cosmetic applications. Additionally, phytosomes exhibit superior stability due to the chemical bonds formed between phosphatidylcholine molecules and phytoconstituents (shown in fig.3) [32].

The term "phyto" signifies plant, while "some" denotes cell-like. Utilizing phytosomes represented a novel and advanced dosage formulation technology aimed at enhancing the delivery of herbal products and drugs, thereby facilitating improved absorption and consequently yielding superior outcomes compared to those achieved through conventional herbal extracts. The phytosome technology represented a breakthrough model for substantially enhancing bioavailability, providing significantly greater clinical benefits, ensuring delivery to the tissues, all while maintaining nutrient safety standards. Some water-soluble phyto-molecules, particularly flavonoids and other polyphenols, can be transformed into lipid-friendly complexes known as phytosomes by combining herbal drugs with phospholipids. These phytosomes exhibit higher bioavailability compared to simple herbal extracts due to their improved ability to traverse lipid-rich bio-membranes and ultimately enter the bloodstream. They demonstrated enhanced pharmacokinetic and pharmacological characteristics, which proved advantageous in treating acute illnesses as well as in formulating pharmaceutical and cosmetic products [33,34].



Fig.3 Structure of phytosomes

ADVANTAGES OF PHYTOSOMES [35].

1. Phytosomes ensure precise drug delivery to specific tissues.
2. Herbal extract safety remains intact as the herbal drug is conveyed via phytosomes.
3. Reduced dosage requirements due to enhanced absorption of minor constituents.
4. Substantial improvement in drug bioavailability is observed.
5. Phytosomes exhibit high entrapment capacity, predetermined by the lipid-conjugated drug vesicles.
4. Drug entrapment during phytosome formulation poses no issues, contributing to good stability profiles facilitated by chemical bonds between phosphatidylcholine molecules and herbal phytoconstituents.
5. Phosphatidylcholine, a carrier in phytosome formulation, also serves as a skin nourisher.
6. Phytosomes demonstrate significantly enhanced clinical benefits.

DISADVANTAGES OF PHYTOSOMES [36].

1. Despite their advantages, phytosomes may lead to the rapid exclusion of phytoconstituents.
2. Phospholipids could potentially stimulate proliferation in the MCF-7 breast cancer cell line.
3. The primary limitation of phytosomes is the reported leaching of phytoconstituents from the formulation, resulting in decreased drug concentration as anticipated.

APPLICATION OF PHYTOSOMES

1. Enhancing Bioavailability: Several factors contribute to the low oral bioavailability of phytoconstituents, including dosage form, low concentrations post-chemical degradation, physical inactivation, and elimination via the gut wall and liver. Nonetheless, enhanced bioavailability achieved through oral administration of phytosomes stems from increased hydrophilicity and solubility, reduced hepatic metabolism, and enhanced drug absorption into the systemic circulation [37].

2. Antioxidant properties: In a study published in 2014 by B. Demir et al., metal phytosome was created by encapsulating Calendula officinalis extract, investigating its anti-oxidative properties.

Analysis of reactive oxygen species was conducted through an in vitro cell-based antioxidant assay using Vero cell lines. Results showed that cell viability was around 35% for the plant extract and 81% for the Au-loaded phytosome[38].

3. Hepato- protective: The leaf extracts of Ginkgo biloba (Family: Ginkgoaceae) exhibit various beneficial properties including cardioprotective, anti-asthmatic, anti-diabetic, antioxidant, hepatoprotective, and potent CNS activities. In the study, it was observed that phytosomes derived from G. biloba (at a dosage of 200mg/kg) significantly mitigated isoproterenol-induced myocardial necrosis. Histopathological analysis of the myocardium further validated the cardioprotective effects of phytosomes. The observed reduction in myocardial necrosis, as indicated by decreased AST, LDH, and CPK release along with histological changes, coupled with the enhancement of endogenous antioxidants, collectively contribute to its cardioprotective potential [39].

4. Wound healing: In 2016, Mazumder et al. conducted a study on the wound healing potential of Sinigrin, a prominent glucosinolate found in plants of the Brassicaceae family. The research evaluated Sinigrin alone and as a phytosome complex on HaCaT cells. Results showed that the sinigrin-phytosome complex achieved full wound recovery (100%), whereas the isolated phytoconstituent exhibited only 71% healing. Additionally, Sinigrin phytosomes demonstrated enhanced anti-cancer activity on A-375 melanoma cells [40].

METHODS FOR PREPARATION OF PHYTOSOMES

1. Solvent evaporation method

The solvent evaporation method combines the phytoconstituents and PC within a flask containing an organic solvent. This mixture is maintained at an optimal temperature, typically 40°C, for a specific duration of 1 hour to achieve maximal drug entrapment within the formed phytosomes. Thin film phytosomes are then separated using 100 mesh sieves and stored in desiccators overnight [41]

2. Mechanical dispersion method

During the experiments, lipids dissolved in organic solvents are mixed with an aqueous phase containing the drug. Subsequent removal of the organic solvent under reduced pressure leads to the creation of phyto-phospholipid complexes. Recently, methods for phospholipid encapsulation preparation have included supercritical fluids (SCF), such as the gas anti-solvent technique (GAS), compressed anti-solvent process (PCA), and supercritical anti-solvent method (SAS) [42]

3. Salting out technique

A significant technique for phytosome preparation involves dissolving both phosphatidylcholine (PC) and the plant extract in an appropriate organic solvent. Subsequently, n-hexane is added until the precipitation of the extract-PC complex occurs [43].

4. Anti solvent precipitation process

A specific quantity of herbal extract and phospholipids undergo reflux with 20ml of organic solvents such as acetone under experimental conditions maintained below 50°C for 2-3 hours. The reaction mixture is then concentrated to a minimum volume of 10ml. Subsequently, upon the addition of a low-polarity solvent like n-hexane with stirring, precipitates form. The filtered precipitates are stored in desiccators. The dried precipitates are pulverized, and the resulting powdered complex is stored in dark, amber-colored glass bottles at a controlled temperature [44].

5. Rotary evaporation process

A specific amount of herbal extract and phospholipids were combined in 30ml of a water-miscible organic solvent like acetone in a round-bottom glass vessel, followed by stirring for two hours at a

temperature below 50°C using a rotary evaporator. An anti-solvent such as n-hexane is often introduced to the thin film formed after continuous stirring with a stirrer. The precipitated phytosomes can be stored in amber-colored glass containers at a controlled temperature and humidity. Phospholipids dissolved in ether are gradually added drop by drop to a solution of the phytoconstituents intended for encapsulation. This process leads to the formation of cellular vesicles upon subsequent removal of the solvent, resulting in the formation of phytosome complexes. The structure of phytosomes is dependent on the concentration of amphiphiles; a lower concentration yields structures in a monomeric state, while various shapes such as round, cylindrical, disc-shaped, and cubic or hexagonal vesicles may form as the concentration increases [45].

FORMULATION OF PHYTOSOME DRUG DELIVERY SYSTEM

PRODUCTS	COMPOSITIONS	OBJECTIVE STUDY	REFERENCE
Curcumin phytosomes	Carageenan,curcumin,indo methacin,ethanol,phospha te buffer pH 7.4, tween 80	Improves absorption and anti-inflammatory effect	[46,47]
Silybin phytosomes	Silybin-phospholipon 1:04, methanol-chloroform 1:4	Suppressing oxidative stress and reducing inflammatory response	[48,49]
Greenselect phytosomes	Epigallocatechin 3-o-gallate extracts:soya lecithin 1:1	It boosts the extracts bioactivity and bioavailability	[50]
Silymarin phytosomes	Silybum marianum extract,phospholipid	Antioxidant activity and hepato-protective activity	[51,52]
Quercetin phytosomes	Quercetin, Sunflower lecithin 1:1	Higher solubility than unformulated quercetin and antioxidant activity	[53,54]
Domperidone phytosomes	Domperidone - phosphatidylcholine 1:1, piperine 1mg, ethanol 30ml	Enhance bioavailability and improved the oral pharmacokinetic of domperidone	[55,56]
Mitomycin phytosomes	Mitomycin - phosphatidylcholine 1:1	Cytotoxic agent,antiproliferative and anticancer agent	[57,58]

EVALUATION PARAMETERS OF PHYTOSOMES

VISUALIZATION: The visualization of phytosomes was achieved through the application of scanning electron microscopy. This technique had been employed to determine the distribution of particle sizes and the surface morphology of the complex. Prior to examination, the samples underwent sputter-coating with gold/palladium for 120seconds at 14 mA in an argon atmosphere for secondary electron emission SEM (Hitachi-S 3400N). Morphological observations were conducted at a voltage of 15.0 kV [59]

PARTICLE SIZE AND SIZE DISTRIBUTION: The particle size, distribution, and zeta potential of the optimized phytosome formulation were assessed through dynamic light scattering (DLS) with a computerized examination system (Malvern Zetamaster ZEM 5002, Malvern, UK). The electric potential, including the Stern layer (zeta potential), of the phytosomes was evaluated by introducing the diluted system into a zeta potential measurement cell [60]

DRUG ENTRAPMENT EFFICIENCY: 100mg of prepared phytosomes were dried properly and dispersed in 50ml distilled water, The content was stirred for 2h and filtered through in whatman filter paper of pore size 45µm. It was then suitably diluted and analyzed spectrophotometrically at λmax 332 [61]

The amount of drug entrapped was Calculated from the standard curve using the formula:

Drug Entrapment Efficiency (%) = [(Total Drug - Free Drug) / Total Drug] × 100

Where:

- Total Drug: Initial amount of drug added to the formulation.
- Free Drug: Amount of drug remaining unentrapped in the supernatant after centrifugation.

INVTRO DISSOLUTION RATE STUDIES: The in vitro drug release study for the sample was conducted utilizing a USP-type I dissolution apparatus (Basket type). A dissolution medium consisting of 900ml 0.1N HCl was poured into the dissolution flask, maintaining a temperature of 37±0.5°C and a stirring speed of 75rpm. Each basket of the dissolution apparatus contained 10mg of the prepared phytosomes. The experiment ran for 8 hours, with 3 ml samples withdrawn at specified intervals (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, and 12 hours) using a 10ml pipette. After each withdrawal, fresh dissolution medium (37°C) was replenished in the same quantity as the sample, and absorbance was measured at 256.0 nm using spectroscopy [62]

CHALLENGES

1. Tackling Drug Resistance: Confronting the rise of drug-resistant malaria strains presents a significant obstacle in malaria treatment strategies [63]
2. Ensuring Stability: Guaranteeing the stability of phytosome formulations throughout storage and transportation is critical to maintaining their clinical effectiveness [64]
3. Improving Formulation: Striving to achieve optimal drug entrapment efficiency and dissolution rates remains a persistent challenge in the advancement of phytosome formulations [65]
4. Cost-efficiency: Developing economically viable phytosome formulations accessible to malaria-endemic regions is imperative for widespread utilization and impact.

FUTURE DIRECTION [66]

1. Integration of Nanotechnology: Exploring the integration of nanotechnology-based strategies to enhance the delivery and effectiveness of phytosomes in treating malaria
2. Combination Therapy Investigation: Researching the potential synergistic benefits of combining phytosomes with existing antimalarial medications to address drug resistance issues
3. Targeted Delivery Design: Developing targeted phytosome formulations aimed at improving drug specificity and minimizing adverse reactions
4. Clinical Trial Implementation: Implementing robust clinical trials to assess the asafety and efficacy of phytosomes in malaria patients, ensuring thorough evaluation before widespread use

CONCLUSION

Phytosomes represent a promising strategy for the treatment of malaria, offering improved drug delivery, bioavailability, and therapeutic efficacy compared to conventional treatments. Despite existing challenges, ongoing research efforts and advancements in formulation techniques hold great potential for the development of effective phytosome-based antimalarial therapies. Collaborative initiatives involving interdisciplinary research, clinical trials, and community engagement are essential for realizing the full therapeutic benefits of phytosomes in malaria management.

REFERENCES

1. Varo, R., Chaccour, C., & Bassat, Q. (2020). Update on malaria. *Medicina Clínica (English Edition)*, *155*(9), 395-402.
2. Liu, Q., Jing, W., Kang, L., Liu, J., & Liu, M. (2021). Trends of the global, regional and national incidence of malaria in 204 countries from 1990 to 2019 and implications for malaria prevention. *Journal of Travel Medicine*, *28*(5), taab046.
3. Diouf, I., Adeola, A. M., Abiodun, G. J., Lennard, C., Shirinde, J. M., Yaka, P., ... & Gbobaniyi, E. O. (2022). Impact of future climate change on malaria in West Africa. *Theoretical and Applied Climatology*, 1-13.
4. Nissan, H., Ukawuba, I., & Thomson, M. (2021). Climate-proofing a malaria eradication strategy. *Malaria journal*, *20*, 1-16.
5. Abuga, K. M., Jones-Warner, W., & Hafalla, J. C. R. (2021). Immune responses to malaria pre-erythrocytic stages: implications for vaccine development. *Parasite immunology*, *43*(2), e12795.
6. Pryce, J., Taylor, M., Fox, T., & Hine, P. (2022). Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. *Cochrane Database of Systematic Reviews*, (6).
7. Klope, M. (2023). *Towards New Antimalarial Drug Candidates From the Endoperoxide Class*. University of California, San Francisco.
8. Niguram, P., & Kate, A. S. (2022). Comprehensive metabolite identification study of arterolane using hydrophilic interaction liquid chromatography with quadrupole-time-of-flight mass spectrometry. *Rapid Communications in Mass Spectrometry*, *36*(16), e9335.
9. Ward, K. E., Fidock, D. A., & Bridgford, J. L. (2022). Plasmodium falciparum resistance to artemisinin-based combination therapies. *Current opinion in microbiology*, *69*, 102193.
10. Li, G., Yuan, Y., Zheng, S., Lu, C., Li, M., Tan, R., ... & Deng, C. (2022). Artemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Grande Comore island: an open-label, non-randomised controlled trial. *International Journal of Antimicrobial Agents*, *60*(4), 106658.
11. Ali, A. M., Gausi, K., Jongo, S. A., Kassim, K. R., Mkindi, C., Simon, B., ... & Penny, M. A. (2022). Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization. *Antimicrobial Agents and Chemotherapy*, *66*(5), e01696-21.
12. Daily, J. P., Minuti, A., & Khan, N. (2022). Diagnosis, treatment, and prevention of malaria in the US: a review. *Jama*, *328*(5), 460-471.
13. Raza, M., Bharti, H., Chauhan, C., Singal, A., Jha, D., Ghosh, P. C., & Nag, A. (2024). Enhanced anti-malarial efficacy of mefloquine delivered via cationic liposome in a murine model of experimental cerebral malaria. *European Journal of Pharmaceutics and Biopharmaceutics*, 114210.
14. Kantele, A., Mero, S., & Lääveri, T. (2022). Doxycycline as an antimalarial: Impact on travellers' diarrhoea and doxycycline resistance among various stool bacteria-Prospective study and literature review. *Travel medicine and infectious disease*, *49*, 102403.
1. 15 Camprubí-Ferrer, D., Oteo, J. A., Bottieau, E., Genton, B., Balerdi-Sarasola, L., Portillo, A., ... & Muñoz, J. (2023). Doxycycline responding illnesses in returning travellers with undifferentiated non-malaria fever: a European multicentre prospective cohort study. *Journal of travel medicine*, *30*(1), taac094.

15. Pugliese, N., Samarelli, R., Lombardi, R., Schiavone, A., Crescenzo, G., Circella, E., ... & Camarda, A. (2023). A Safe and Effective Atovaquone-Proguanil Therapeutic Protocol for the Treatment of Avian Malaria by Plasmodium relictum in Snowy Owl (Bubo scandiacus). *Animals*, *13*(22), 3457.
16. BAIDYA, A. (2023). Artesunate versus Quinine for Severe Falciparum Malaria. *50 Studies Every Global Health Provider Should Know*, 144.
2. 18 Keating, C. (2023). Artesunate versus quinine: the controlled trials watershed. *The Lancet*, *401*(10385), 1329-1331.
3. 19. Saeheng, T., & Na-Bangchang, K. (2022). Clinical pharmacokinetics of quinine and its relationship with treatment outcomes in children, pregnant women, and elderly patients, with uncomplicated and complicated malaria: a systematic review. *Malaria Journal*, *21*(1), 41.
4. 20. Miller, L. H., Rojas-Jaimes, J., Low, L. M., & Corbellini, G. (2023). What Historical Records Teach Us about the Discovery of Quinine. *The American Journal of Tropical Medicine and Hygiene*, *108*(1), 7.
5. 21. Stepniewska, K., Allen, E. N., Humphreys, G. S., Poirot, E., Craig, E., Kennon, K., ... & Chen, I. (2022). Safety of single dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data. *BMC medicine*, *20*(1), 350.
6. 22. Verma, R., Commons, R. J., Gupta, A., Rahi, M., Bharti, P. K., Thriemer, K., ... & Sharma, A. (2023). Safety and efficacy of primaquine in patients with Plasmodium vivax malaria from South Asia: a systematic review and individual patient data meta-analysis. *BMJ Global Health*, *8*(12), e012675.
7. 23. Hanboonkunupakarn, B., & White, N. J. (2022). Advances and roadblocks in the treatment of malaria. *British journal of clinical pharmacology*, *88*(2), 374-382.
8. 24. Schmitt, E. K., Ndayisaba, G., Yeka, A., Asante, K. P., Grobusch, M. P., Karita, E., ... & Gandhi, P. (2022). Efficacy of cipargamin (KAE609) in a randomized, Phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria. *Clinical Infectious Diseases*, *74*(10), 1831-1839.
9. 25. Pfeffer, S., Otsyula, N., Nicholls, I., Kos, C., Kolly, C., & Gandhi, P. (2023). PA-282 Juvenile toxicity program to support use of Cipargamin (KAE609) in paediatric patients with severe malaria.
10. 26. Gansane, A., Lingani, M., Yeka, A., Nahum, A., Bouyou-Akotet, M., Mombo-Ngoma, G., ... & Ogutu, B. (2023). Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria. *Malaria Journal*, *22*(1), 2.
11. 27. Yipsirimetee, A., Chiewpoo, P., Tripura, R., Lek, D., Day, N. P., Dondorp, A. M., ... & Chotivanich, K. (2022). Assessment in vitro of the antimalarial and transmission-blocking activities of Cipargamin and Ganaplacide in Artemisinin-resistant Plasmodium falciparum. *Antimicrobial Agents and Chemotherapy*, *66*(3), e01481-21.
12. 28. Abubakar, T. A., Eke, U. B., & Salisu, A. (2022). Bioorganometallic Ferroquine and Related Compounds as Antimalarial Chemotherapeutic Agents: A Short Review. *Journal of Chemical Society of Nigeria*, *47*(3).
13. 29. Jovanović, A., & Krajnović, D. (2023). The developmental path of quinine: What can we learn from history?. *Acta Medica Medianae*, *62*(2).
14. 30. Fazal, T. M. (2024). *Military Medicine and the Hidden Costs of War*. Oxford University Press.
15. 31. Nyaaba, N., Andoh, N. E., Amoh, G., Amuzu, D. S. Y., Ansong, M., Ordóñez-Mena, J. M., & Hirst, J. (2022). Comparative efficacy and safety of the artemisinin derivatives compared to

quinine for treating severe malaria in children and adults: A systematic update of literature and network meta-analysis. *Plos one*, *17*(7), e0269391..

16. 32. Shewale, A., Yadav, A. R., & Ashwini, S. J. (2022). Novel drug delivery systems and its future prospects. *J Univ Shanghai Sci Technol*, *24*, 48-60.
17. 33. Chen, R. P., Chavda, V. P., Patel, A. B., & Chen, Z. S. (2022). Phytochemical delivery through transferosome (phytosome): an advanced transdermal drug delivery for complementary medicines. *Frontiers in Pharmacology*, *13*, 850862.
18. 34. Islam, N., Irfan, M., Hussain, T., Mushtaq, M., Khan, I. U., Yousaf, A. M., ... & Shahzad, Y. (2022). Piperine phytosomes for bioavailability enhancement of domperidone. *Journal of Liposome Research*, *32*(2), 172-180.
19. 35. Kumar, R., Kumar, K., Teotia, D., Khairya, D., & Joshi, A. (2022). Phytosomes as an innovative technique in novel drug delivery system: a comprehensive review. *International Journal of Current Innovations in Advanced Research*, 1-7.
20. 36. Pandya, B. D., & Saluja, A. K. A REVIEW ON PHYTOSOMES: A POTENTIAL NANOCARRIER FOR EMERGING DRUG DELIVERY OF PHYTOCONSTITUENTS.
21. 37. Dutt, Y., Pandey, R. P., Dutt, M., Gupta, A., Vibhuti, A., Raj, V. S., ... & Priyadarshini, A. (2023). Liposomes and phytosomes: nanocarrier systems and their applications for the delivery of phytoconstituents. *Coordination Chemistry Reviews*, *491*, 215251.
22. 38. Demir, B., Barlas, F. B., Guler, E., Gumus, P. Z., Can, M., Yavuz, M., ... & Timur, S. (2014). Gold nanoparticle loaded phytosomal systems: synthesis, characterization and in vitro investigations. *RSC advances*, *4*(65), 34687-34695.
23. 39. Panda, V. S., & Naik, S. R. (2008). Cardioprotective activity of Ginkgo biloba phytosomes in isoproterenol-induced myocardial necrosis in rats: a biochemical and histoarchitectural evaluation. *Experimental and toxicologic pathology*, *60*(4-5), 397-404.
24. 40. Mazumder, A., Dwivedi, A., Du Preez, J. L., & Du Plessis, J. (2016). In vitro wound healing and cytotoxic effects of sinigrin-phytosome complex. *International journal of pharmaceutics*, *498*(1-2), 283-293.
25. 41. Mehmood, H. (2023). Phytosome as a Novel Carrier for Delivery of Phytochemicals: A Comprehensive Review.
26. 42. Wakde, I. P., Biyani, D. M., & Umekar, M. J. (2022). PHYTOSOMES: A GOOD STRATERGY FOR FORMULATION OF HERBAL MEDICINES.
27. 43. Patel, P. M., Modi, C. M., Patel, H. B., Patel, U. D., Ramchandani, D. M., Patel, H. R., & Paida, B. V. (2023). Phytosome: An Emerging Technique for Improving Herbal Drug Delivery.
28. 44. Revankar, R. M., Desai, A. V., & Chougule, N. B. (2024). Development and characterization of Phytosome as a novel carrier by QbD approach. *International Journal of Pharmaceutical Sciences*, *2*(01), 1-1.
29. 45. Vali, C. S., Khan, A., Jaffer, S. M., Kumar, R., Prasad, S. S., Mare, P. B., ... & Rawisandran, S. (2022). Preparation Of Ginkgo Phytosomes By Rotary Evaporation Technique And Its Evaluation. *NeuroQuantology*, *20*(9), 492.
30. 46. Ullah, F., Liang, H., Niedermayer, G., Münch, G., & Gyengesi, E. (2020). Evaluation of phytosomal curcumin as an anti-inflammatory agent for chronic glial activation in the GFAP-IL6 mouse model. *Frontiers in Neuroscience*, *14*, 512270.
31. 47. Baradaran, S., Hajizadeh Moghaddam, A., Khanjani Jelodar, S., & Moradi-Kor, N. (2020). Protective effects of curcumin and its nano-phytosome on carrageenan-induced inflammation in mice model: behavioral and biochemical responses. *Journal of inflammation research*, 45-51.

32. 48. Pasala, P. K., Uppara, R. K., Rudrapal, M., Zothantluanga, J. H., & Umar, A. K. (2022). Silybin phytosome attenuates cerebral ischemia-reperfusion injury in rats by suppressing oxidative stress and reducing inflammatory response: In vivo and in silico approaches. *Journal of Biochemical and Molecular Toxicology*, *36*(7), e23073.
33. 49. Chi, C., Zhang, C., Liu, Y., Nie, H., Zhou, J., & Ding, Y. (2020). Phytosome-nanosuspensions for silybin-phospholipid complex with increased bioavailability and hepatoprotection efficacy. *European journal of pharmaceutical sciences*, *144*, 105212.
34. 50. Saleemi, M. A., & Lim, V. (2022). Phytosomes used for herbal drug delivery. In *Pharmaceutical Nanobiotechnology for Targeted Therapy* (pp. 255-279). Cham: Springer International Publishing.
35. 51. Elyasi, S. (2021). Silybum marianum, antioxidant activity, and cancer patients. In *Cancer* (pp. 483-493). Academic Press.
36. 52. Marceddu, R., Dinolfo, L., Carrubba, A., Sarno, M., & Di Miceli, G. (2022). Milk thistle (Silybum Marianum L.) as a novel multipurpose crop for agriculture in marginal environments: A review. *Agronomy*, *12*(3), 729.
37. 53. Riva, A., Ronchi, M., Petrangolini, G., Bosisio, S., & Allegrini, P. (2019). Improved oral absorption of quercetin from quercetin phytosome®, a new delivery system based on food grade lecithin. *European journal of drug metabolism and pharmacokinetics*, *44*, 169-177.
38. 54. Vu, T. T. G., Pham, T. M. H., & Nguyen, H. T. (2022). Preparation and Valuation of Capsules Containing Quercetin Phytosome for Hepatoprotective Activity. *VNU Journal of Science: Medical and Pharmaceutical Sciences*, *38*(4).
39. 55. Islam, N., Irfan, M., Hussain, T., Mushtaq, M., Khan, I. U., Yousaf, A. M., ... & Shahzad, Y. (2022). Piperine phytosomes for bioavailability enhancement of domperidone. *Journal of Liposome Research*, *32*(2), 172-180.
40. 56. Priya, V. M. H., & Kumaran, A. (2023). Recent Trends in Phytosome Nanocarriers for Improved Bioavailability and Uptake of Herbal Drugs. *Pharmaceutical Sciences*, *29*(3), 298-319.
41. 57. Sasikirana, W., & Ekawati, N. (2021). Phytosome as Cytotoxic agent delivering system: A Review. *Generics: Journal of Research in Pharmacy*, *1*(2), 10-17.
42. 58. Sasikirana, W., & Ekawati, N. (2021). Phytosome as Cytotoxic agent delivering system: A Review. *Generics: Journal of Research in Pharmacy*, *1*(2), 10-17.
43. 59. Jain, A., Verma, R., & Mehta, P. D. (2023). Formulation and Evaluation of Phytosomes Loaded with Pithecellobium Bijeninum Leaf Extract. *Current Research in Pharmaceutical Sciences*, 151-156.
44. 60. Chouhan, A., Shah, S. K., Tyagi, C., Budholiya, P., Wazid, A., & Khan, F. (2021). Formulation, development and evaluation of phytosomes of swertia perennis. *Asian J. Pharm. Educ. Res*, *10*, 55-56.
45. 61. Singh, A., & Prasad, S. (2023). The Development and Evaluation of the Anti-Diabetic Activity of Phytosomes to Enhance the Therapeutic Efficacy of Extracts. *Latin American Journal of Pharmacy: A Life Science Journal*, *42*(5), 595-611.
46. 62. Singh, S., & Singh, N. (2022). Formulation and evaluation of phytosomes of panax ginseng, nymphaea steallata, mucuna pruriens, syzygium cumini and aegle marmelos. *Journal of Population Therapeutics and Clinical Pharmacology*, *29*(04), 1187-1195.
47. 63. Hamilton, A., Haghpanah, F., Hasso-Agopsowicz, M., Frost, I., Lin, G., Schueller, E., ... & Laxminarayan, R. (2023). Modeling of malaria vaccine effectiveness on disease burden and drug resistance in 42 African countries. *Communications Medicine*, *3*(1), 144.

48. 64. Hamilton, A., Haghpanah, F., Hasso-Agopsowicz, M., Frost, I., Lin, G., Schueller, E., ... & Laxminarayan, R. (2023). Modeling of malaria vaccine effectiveness on disease burden and drug resistance in 42 African countries. *Communications Medicine*, *3*(1), 144.
49. 65. Kamireddy, S., Sangeetha, S., & Kosanam, S. (2024). Phytosomal Drug Delivery System: A Detailed Study. *Current Traditional Medicine*, *10*(4), 28-35.
50. 66. Ani, A. C., Emencheta, S. C., Orah, K. J., Upaganlawar, A. B., Prajapati, B. G., Oranu, C. K., & Onyekwe, C. P. (2024). Targeted nanotechnology-based formulations. In *Alzheimer's Disease and Advanced Drug Delivery Strategies* (pp. 347-359). Academic Press.